Ropinirole-dextran sulfate nanoplex for nasal administration against Parkinson's disease: in silico molecular modeling and in vitro-ex vivo evaluation.

Autor: Pardeshi CV; a Industrial Pharmacy Laboratory, Department of Pharmaceutics , R. C. Patel Institute of Pharmaceutical Education and Research , Shirpur , Maharashtra , India., Belgamwar VS; b Department of Pharmaceutical Sciences , RTM Nagpur University , Nagpur , Maharashtra , India.
Jazyk: angličtina
Zdroj: Artificial cells, nanomedicine, and biotechnology [Artif Cells Nanomed Biotechnol] 2017 May; Vol. 45 (3), pp. 635-648. Date of Electronic Publication: 2016 Apr 11.
DOI: 10.3109/21691401.2016.1167703
Abstrakt: Dextran sulfate sodium (DS) was allowed to interact ionically with ropinirole hydrochloride (ROPI HCl, an anti-Parkinsonian agent) to synthesize self-assembled ROPI-DS nanoplex. The preliminary objective behind ROPI-DS complexation was to enhance the partitioning of ROPI HCl and thereby its encapsulation into nanocarriers and to improve the nasal membrane permeability. Molecular interactions were computed using in silico molecular modeling. Nanoplex were characterized for physicochemical and partitioning behavior. Optimized ROPI-DS nanoplex was further characterized by spectroscopic and thermal analysis, diffraction studies, morphological and histopathological analysis. In summary, ROPI-DS nanoplex represents a promising nanocarrier material for intranasal administration.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje